Novartis Targets $830 Million CSU Market with New Drug Developments
Recently, Novartis has made significant strides in the chronic spontaneous urticaria (CSU) market, announcing a priority review application for its BTK inhibitor Remibrutinib and a $830 million deal to acquire Kyorin's clinical-stage MRGPRX2 antagonist.
The announcement highlights Novartis' commitment to maintaining its leadership position in the CSU treatment landscape, which is marked by a prevalence rate of approximately 0.05% to 3%, with CSU accounting for about 68% of chronic urticaria cases. The condition primarily manifests as hives and itching, and can lead to deeper systemic issues, increasing the risk of autoimmune diseases and cancers. First-line treatment typically involves H1 antihistamines, but nearly half of patients struggle to achieve adequate control, necessitating additional therapies.
The global CSU market is projected to grow from $779.28 million in 2024 to $1.54141 billion by 2032, with a compound annual growth rate (CAGR) of 8.90% from 2025 to 2032. As awareness and treatment demands increase, this market is poised for continued growth.
As a market leader, Novartis has long relied on its collaboration with Roche to dominate the CSU field with Xolair (omalizumab), an anti-IgE drug that has generated over $4.3 billion in sales in 2024, despite emerging competition. However, with the expiration of Xolair's compound patent and an impending expiry of its formulation patent in November 2025, Novartis faces pressure from competitors like Sanofi/Regenron's Dupixent (dupilumab), which has recently gained approval for CSU in Japan and is challenging Xolair's dominance.
In light of these developments, Novartis has shifted its focus to exploring next-generation therapies, particularly BTK inhibitors. Bruton’s tyrosine kinase (BTK) plays a crucial role in CSU's pathogenesis, and inhibiting BTK can prevent mast cell activation and the production of autoantibodies, addressing two primary pathological mechanisms of CSU.
Last year, Novartis reported positive results from two pivotal Phase III trials of Remibrutinib, demonstrating significant symptom improvement over 52 weeks. The recent submission of its New Drug Application (NDA) positions Remibrutinib as a potential successor to Xolair, aiming to solidify Novartis' standing in the CSU market.
In addition to Remibrutinib, Novartis is strategically acquiring promising candidates like KRP-M223, an MRGPRX2 antagonist, which is anticipated to enhance its portfolio in this therapeutic area. MRGPRX2, a G protein-coupled receptor expressed predominantly on mast cells, is activated during allergic responses, leading to the release of mediators such as histamine. Although KRP-M223 is still in preclinical stages, its unique mechanism holds the potential for significant advancements in treating CSU and related allergic conditions.
In the domestic market, several promising therapies targeting CSU are advancing through clinical trials. Notably, Tianchen Biotech's LP-003, a next-generation anti-IgE antibody, recently reported mid-stage Phase II clinical data that surpassed Xolair's efficacy. With a dosing regimen of every 8 weeks, LP-003 could significantly improve patient compliance compared to Xolair's more frequent administration.
Another contender is Jimin Xinke's JYB1904, a long-acting anti-IgE antibody that boasts a half-life more than twice that of Xolair, reducing injection frequency and potentially enhancing patient adherence to treatment.
As Novartis strengthens its position in the CSU market with innovative therapies and strategic acquisitions, the competitive landscape continues to evolve. The battle for dominance in this lucrative market is intensifying, with Novartis poised to defend its title against emerging threats while exploring new growth avenues.
2026-10-29
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
IMCD Opens Beauty and Personal Care Lab in California
-
As Middle East Supply Faces Disruptions, SABIC's 1.8 Million Mt/Year Methanol New Project Secures Saudi Feedstock Quota
-
South Korea Moves Urgently to Control Petrochemical Feedstock Hoarding as Supply Chain Risk Escalates to the National Security Level
-
“Shutdown Equals Price Hike”: TDI Market Enters a New Era of “Scarcity Games”
-
Haldia Petrochemicals Pipeline Fire in India Adds Uncertainty to Asia's Naphtha Market
-
Sinochem International Acquires Nantong Xingchen for 2.11 Billion Yuan, Rike Chemical Plans Genyuan New Materials Acquisition – The Changing Landscape of Chemical M&A
-
CordenPharma Invests €80 Million to Raise Sterile Injectable Capacity to 500 Million Units Annually
-
AkzoNobel Reports €388 Million Q3 Adjusted EBITDA as Margins Improve for Sixth Straight Quarter
-
ZPC Plans 1.2 Million-Tonne PDH Unit, Setting a New Global Licensing Record
-
Starboard Discloses Stake in Solstice, Calls for $100 Million in Cost Cuts
Recommend Reading
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
BASF Brings Biomass-Balance Polyols to North America
-
Bayer’s Flubendiamide Business Acquired by Tagros, Bringing a New Operator to Markets in Over 25 Countries Worldwide
-
Due to Supply Chain Disruptions, A Major MDI/TDI Facility in the Middle East has Suddenly Shut Down!
-
Henkel to Acquire Olaplex in $1.4 Billion Deal
-
2026 Mid-Autumn Festival & National Day Holiday Notice
-
2025 Review and 2026 Outlook of the Methanol Market in China
-
International Oil Prices Experience a "Heart-Stopping Day" as U.S.-Iran Tensions Trigger Massive Shockwaves in the Energy Market
-
France’s Vineyards Find a New Shield: Eden’s Mevalone Enters the Frontline of a Changing Fungicide Era
-
India Unleashes a Triple-Action Defender: Parijat Introduces NILANIX SC into the Rice Battlefront